Literature DB >> 27059708

Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database.

Yashashwi Pokharel1, Julia M Akeroyd2,3,4, David J Ramsey2,3,4, Ravi S Hira2, Vijay Nambi5,2,6,4, Tina Shah2,4, LeChauncy D Woodard2,3,4, David E Winchester7,8, Christie M Ballantyne5,2,6, Laura A Petersen2,3,4, Salim S Virani5,2,6,3,4.   

Abstract

We sought to determine use of any and at least moderate-intensity statin therapy in a national sample of patients with diabetes mellitus (DM), with the hypothesis that nationwide frequency and facility-level variation in statin therapy are suboptimal. We sampled patients with DM age 40 to 75 years receiving primary care between October 1, 2012, and September 30, 2013, at 130 parent facilities and associated community-based outpatient clinics in the Veterans Affairs Health Care System. We examined frequency and facility-level variation in use of any or at least moderate-intensity statin therapy (mean daily dose associated with ≥30% low-density lipoprotein cholesterol lowering). In 911 444 patients with DM, 68.3% and 58.4% were receiving any and moderate- to high-intensity statin therapy, respectively. Patients receiving statin had higher burden of cardiovascular disease, were more likely to be on nonstatin lipid-lowering therapy and to receive care at a teaching facility, and had more frequent primary-care visits. Median facility-level uses of any and at least moderate-intensity statin therapy were 68.7% (interquartile range, 65.9%-70.8%) and 58.6% (interquartile range, 55.8%-61.4%), respectively. After adjusting for several patient-related and some facility-related characteristics, the median rate ratios for any and moderate- to high-intensity statin therapy were 1.20 (95% confidence interval: 1.18-1.22) and 1.29 (95% confidence interval: 1.24-1.33) respectively, indicating 20% to 29% variation in statin use between 2 identical patients receiving care at 2 random facilities. Statin use was suboptimal in a national sample of patients with DM with modest facility-level variation, likely indicating differences in statin-prescribing patterns.
© 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27059708      PMCID: PMC4840034          DOI: 10.1002/clc.22503

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  20 in total

1.  Medscape's response to the Institute of Medicine Report: Crossing the quality chasm: a new health system for the 21st century.

Authors:  M Leavitt
Journal:  MedGenMed       Date:  2001-03-05

2.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

3.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

4.  Treating chronically ill people with diabetes mellitus with limited life expectancy: implications for performance measurement.

Authors:  LeChauncy D Woodard; Cassie R Landrum; Tracy H Urech; Jochen Profit; Salim S Virani; Laura A Petersen
Journal:  J Am Geriatr Soc       Date:  2012-01-19       Impact factor: 5.562

5.  Assessing appropriateness of lipid management among patients with diabetes mellitus: moving from target to treatment.

Authors:  Ashley J Beard; Timothy P Hofer; John R Downs; Michelle Lucatorto; Mandi L Klamerus; Rob Holleman; Eve A Kerr
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-12-11

6.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Authors:  Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood
Journal:  Eur Heart J       Date:  2011-06-28       Impact factor: 29.983

Review 7.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

8.  Executive summary: Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

9.  Impact of clinical complexity on the quality of diabetes care.

Authors:  LeChauncy D Woodard; Cassie R Landrum; Tracy H Urech; Degang Wang; Salim S Virani; Laura A Petersen
Journal:  Am J Manag Care       Date:  2012-09       Impact factor: 2.229

10.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.

Authors:  P M Kearney; L Blackwell; R Collins; A Keech; J Simes; R Peto; J Armitage; C Baigent
Journal:  Lancet       Date:  2008-01-12       Impact factor: 79.321

View more
  13 in total

1.  Lipid-Lowering Prescription Patterns in Patients With Diabetes Mellitus or Cardiovascular Disease.

Authors:  Alanna M Chamberlain; Sarah S Cohen; Jill M Killian; Keri L Monda; Susan A Weston; Ted Okerson
Journal:  Am J Cardiol       Date:  2019-07-15       Impact factor: 2.778

2.  Still Asking "Which Rate Is Right?" Years Later.

Authors:  Tyler B Woodell; Dena E Rifkin
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-29       Impact factor: 8.237

3.  Facility-level variation in diabetes and blood pressure control in patients with diabetes: Findings from the Veterans Affairs national database.

Authors:  Hasan Rehman; Julia M Akeroyd; David Ramsey; Sarah T Ahmed; Anwar T Merchant; Sankar D Navaneethan; Laura A Petersen; Salim S Virani
Journal:  Clin Cardiol       Date:  2017-08-25       Impact factor: 2.882

4.  Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD.

Authors:  Sankar D Navaneethan; Julia M Akeroyd; David Ramsey; Sarah T Ahmed; Shiva Raj Mishra; Laura A Petersen; Paul Muntner; Christie Ballantyne; Wolfgang C Winkelmayer; Venkat Ramanathan; Salim S Virani
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-29       Impact factor: 8.237

5.  Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large US managed-care population.

Authors:  Dylan L Steen; Irfan Khan; Laura Becker; JoAnne M Foody; Katherine Gorcyca; Robert J Sanchez; Robert P Giugliano
Journal:  Clin Cardiol       Date:  2016-12-27       Impact factor: 2.882

6.  Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.

Authors:  Dhruv Mahtta; David J Ramsey; Michelle T Lee; Liang Chen; Mahmoud Al Rifai; Julia M Akeroyd; Elizabeth M Vaughan; Michael E Matheny; Karla Rodrigues do Espirito Santo; Sankar D Navaneethan; Carl J Lavie; Yochai Birnbaum; Christie M Ballantyne; Laura A Petersen; Salim S Virani
Journal:  Diabetes Care       Date:  2022-02-01       Impact factor: 19.112

7.  Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.

Authors:  Salim S Virani; Kevin F Kennedy; Julia M Akeroyd; Pamela B Morris; Vera A Bittner; Frederick A Masoudi; Neil J Stone; Laura A Petersen; Christie M Ballantyne
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-05

8.  Risk of cardiovascular event and mortality in relation to refill and guideline adherence to lipid-lowering medications among patients with type 2 diabetes mellitus in Sweden.

Authors:  Sofia Axia Karlsson; Björn Eliasson; Stefan Franzén; Mervete Miftaraj; Ann-Marie Svensson; Karolina Andersson Sundell
Journal:  BMJ Open Diabetes Res Care       Date:  2019-04-08

9.  Association of Region and Hospital and Patient Characteristics With Use of High-Intensity Statins After Myocardial Infarction Among Medicare Beneficiaries.

Authors:  Vera Bittner; Lisandro D Colantonio; Yuling Dai; Mark Woodward; Matthew T Mefford; Robert S Rosenson; Paul Muntner; Keri L Monda; Meredith L Kilgore; Byron C Jaeger; Emily B Levitan
Journal:  JAMA Cardiol       Date:  2019-09-01       Impact factor: 14.676

10.  Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.

Authors:  Sofia Axia Karlsson; Stefan Franzén; Ann-Marie Svensson; Mervete Miftaraj; Björn Eliasson; Karolina Andersson Sundell
Journal:  BMC Health Serv Res       Date:  2018-11-28       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.